BR112018012873A2 - vacina de vírus zika - Google Patents

vacina de vírus zika

Info

Publication number
BR112018012873A2
BR112018012873A2 BR112018012873-2A BR112018012873A BR112018012873A2 BR 112018012873 A2 BR112018012873 A2 BR 112018012873A2 BR 112018012873 A BR112018012873 A BR 112018012873A BR 112018012873 A2 BR112018012873 A2 BR 112018012873A2
Authority
BR
Brazil
Prior art keywords
zika virus
virus vaccine
vaccines
zika
subjects
Prior art date
Application number
BR112018012873-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Barbero Calzado Jana
Nebenführ Mario
Schlegl Robert
Weber Michael
Wruss Jürgen
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57821924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018012873(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of BR112018012873A2 publication Critical patent/BR112018012873A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112018012873-2A 2015-12-23 2016-12-23 vacina de vírus zika BR112018012873A2 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP15202585 2015-12-23
EP15202585.4 2015-12-23
EP16161068 2016-03-18
EP16161068.8 2016-03-18
EP16176049.1 2016-06-23
EP16176025.1 2016-06-23
EP16176049 2016-06-23
EP16176025 2016-06-23
EP16182845 2016-08-04
EP16182845.4 2016-08-04
PCT/EP2016/082664 WO2017109225A1 (en) 2015-12-23 2016-12-23 Zika virus vaccine

Publications (1)

Publication Number Publication Date
BR112018012873A2 true BR112018012873A2 (pt) 2018-12-04

Family

ID=57821924

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018012873-2A BR112018012873A2 (pt) 2015-12-23 2016-12-23 vacina de vírus zika

Country Status (19)

Country Link
US (14) US10537630B2 (enExample)
EP (9) EP3393506B1 (enExample)
JP (1) JP6949027B2 (enExample)
KR (1) KR20180097558A (enExample)
CN (2) CN115381934A (enExample)
AU (1) AU2016375338B2 (enExample)
BR (1) BR112018012873A2 (enExample)
CA (1) CA3009278A1 (enExample)
DK (1) DK3393510T5 (enExample)
ES (4) ES2950887T3 (enExample)
FI (1) FI3393510T3 (enExample)
HR (1) HRP20230273T1 (enExample)
HU (1) HUE061679T2 (enExample)
LT (1) LT3393510T (enExample)
MX (1) MX2018007627A (enExample)
PL (1) PL3393510T3 (enExample)
SG (1) SG11201805120YA (enExample)
SI (1) SI3393510T1 (enExample)
WO (6) WO2017109223A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895437B2 (en) 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
UA126548C2 (uk) * 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
JP6949027B2 (ja) 2015-12-23 2021-10-20 バルネバ オーストリア ジーエムビーエイチ ジカウイルスワクチン
BR112018077540A2 (pt) * 2016-07-08 2019-10-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
SG11202001161YA (en) 2017-09-21 2020-03-30 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
WO2019090233A2 (en) * 2017-11-03 2019-05-09 Takeda Vaccines, Inc. Method for inactivating zika virus and for determining the completeness of inactivation
CN107988239B (zh) * 2017-11-29 2021-03-19 南方医科大学 一种寨卡病毒的重组基因及其制备方法和应用
JP7443233B2 (ja) * 2017-11-30 2024-03-05 タケダ ワクチン，インコーポレイテッド ジカウイルスを不活性化する方法及び関連する方法
CN107904215B (zh) * 2017-12-27 2021-07-27 华农（肇庆）生物产业技术研究院有限公司 一种禽流感病毒的全悬浮培养方法
TWI658848B (zh) * 2018-02-13 2019-05-11 國立清華大學 茲卡病毒疫苗組合物及其應用
CN110156880B (zh) * 2018-02-13 2022-12-16 吴夙钦 兹卡病毒疫苗组合物及其应用
WO2019191005A1 (en) * 2018-03-26 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
CN108676780B (zh) * 2018-07-24 2021-08-10 华中农业大学 一种高效分离猪肠道冠状病毒的方法
CN109337876A (zh) * 2018-10-15 2019-02-15 北京世纪元亨动物防疫技术有限公司 一种猪流行性腹泻病毒的纯化方法
EP3883961A1 (en) 2018-11-20 2021-09-29 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
CN109627297B (zh) * 2018-12-29 2022-06-14 复旦大学 来自寨卡病毒e蛋白的中和表位及其应用
EP3914067A4 (en) * 2019-01-22 2022-11-02 2seventy bio, Inc. METHODS AND SYSTEMS FOR MAKING VIRAL VECTORS
MX2021011913A (es) * 2019-05-08 2021-12-15 Takeda Vaccines Inc Composiciones de virus inactivado y formulaciones de vacunas contra el zika.
IL290458B2 (en) 2019-08-09 2025-06-01 Valneva Se Chikungunya vaccine formulations
IL290450B2 (en) 2019-08-09 2025-07-01 Valneva Se Single shot chikungunya virus vaccine
WO2021048221A1 (en) 2019-09-09 2021-03-18 Valneva Austria Gmbh Inactivation process for viruses
KR102243295B1 (ko) * 2019-11-15 2021-04-23 강원대학교산학협력단 지카바이러스의 외피 단백질을 포함하는 재조합 백신 조성물
KR102365464B1 (ko) * 2019-12-24 2022-02-22 강원대학교산학협력단 지카바이러스 재조합 서브유닛 백신의 개발 및 이의 제조방법
WO2021158815A1 (en) * 2020-02-05 2021-08-12 New York Blood Center, Inc. Zika virus immunogenic compositions
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
AU2021229710A1 (en) 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
US20230110516A1 (en) 2020-03-01 2023-04-13 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
JP7759333B2 (ja) * 2020-03-03 2025-10-23 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ ジカウイルスポリペプチド
TW202203967A (zh) 2020-04-06 2022-02-01 奧地利商瓦爾尼瓦奧地利有限責任公司 不活化ＳＡＲＳ—ＣｏＶ—２病毒疫苗
US20230204567A1 (en) 2020-05-20 2023-06-29 Takeda Vaccines, Inc. Method for determining the potency of antigens
JP2023526493A (ja) 2020-05-20 2023-06-21 タケダ ワクチン，インコーポレイテッド ジカウイルス特異的抗体の検出方法
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine
WO2023154043A1 (en) * 2022-02-09 2023-08-17 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
WO2025099278A2 (en) * 2023-11-08 2025-05-15 Valneva Austria Gmbh Immunogenic zika virus compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86061A (en) * 1869-01-19 Improved horse-power
CA2301000C (en) 1997-08-28 2003-07-08 Cheil Jedang Corporation An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
ATE471983T1 (de) * 1998-09-02 2010-07-15 Us Gov Health & Human Serv Dengue viren, die in mosquitos nicht replizieren, zur verwendung als impfstoff
CA2410948C (en) 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
WO2002074963A1 (en) * 2001-03-16 2002-09-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Dengue viruses that are replication defective in mosquitos for use as vaccines
US7871814B2 (en) * 2001-05-10 2011-01-18 The Regents Of The University Of California Recombinant bicistronic flaviviruses and methods of use thereof
EP1608402B1 (en) 2003-03-24 2010-10-20 Intercell AG Improved vaccines
WO2008026225A2 (en) * 2006-09-01 2008-03-06 Bharat Biotech International Limited A vaccine for chikungunya virus infection
WO2009048633A2 (en) 2007-10-11 2009-04-16 The Board Of Regents Of The University Of Texas System Chimeric chikungunya virus and uses thereof
BRPI0910686A2 (pt) * 2008-04-21 2015-09-29 Tissue Regeneration Therapeutics Inc células perivasculares do cordão umbilical humano geneticamente modificadas para a profilaxia contra agentes biológicos e químicos ou para o tratamento dos mesmos.
US9353353B2 (en) * 2008-11-26 2016-05-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles (VLPs) prepared from chikungunya virus structural proteins
WO2010085358A2 (en) * 2009-01-23 2010-07-29 The Board Of Regents Of The University Of Texas System Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
ES2930458T3 (es) 2011-12-06 2022-12-13 Valneva Austria Gmbh Compuestos de aluminio para su uso en agentes terapéuticos y vacunas
US9895437B2 (en) * 2012-04-18 2018-02-20 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
WO2016145149A1 (en) 2015-03-11 2016-09-15 The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of The Walter Reed Army Institute Of Research Combination purified inactivated vaccine for flaviviruses
UA126548C2 (uk) 2015-07-16 2022-11-02 Бхарат Біотек Інтернешнл Лімітед Вакцинна композиція для профілактики абровірусних інфекцій
JP6949027B2 (ja) 2015-12-23 2021-10-20 バルネバ オーストリア ジーエムビーエイチ ジカウイルスワクチン
CN105749268B (zh) * 2016-04-11 2020-09-11 北京科兴中维生物技术有限公司 一种灭活的寨卡病毒疫苗
SG11202001161YA (en) 2017-09-21 2020-03-30 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3

Also Published As

Publication number Publication date
EP3393509A1 (en) 2018-10-31
EP4357355A3 (en) 2024-09-25
DK3393510T3 (da) 2023-03-13
JP2019504030A (ja) 2019-02-14
US11207397B2 (en) 2021-12-28
EP4393938A2 (en) 2024-07-03
US12102673B2 (en) 2024-10-01
WO2017109227A1 (en) 2017-06-29
US20200017555A9 (en) 2020-01-16
US20210093707A1 (en) 2021-04-01
ES2976311T3 (es) 2024-07-29
US20200384099A1 (en) 2020-12-10
EP3393507B1 (en) 2024-02-07
US12214033B2 (en) 2025-02-04
US11951163B2 (en) 2024-04-09
EP3393507A1 (en) 2018-10-31
SG11201805120YA (en) 2018-07-30
US11331382B2 (en) 2022-05-17
US10744194B2 (en) 2020-08-18
US20200197506A1 (en) 2020-06-25
EP3393509B1 (en) 2024-02-28
AU2016375338B2 (en) 2021-11-04
EP3393506A1 (en) 2018-10-31
US20180362936A1 (en) 2018-12-20
EP4253403A3 (en) 2023-12-27
WO2017109225A1 (en) 2017-06-29
CN115381934A (zh) 2022-11-25
JP6949027B2 (ja) 2021-10-20
PL3393510T3 (pl) 2023-06-26
EP4253403A2 (en) 2023-10-04
AU2016375338A1 (en) 2018-07-05
CN108697785B (zh) 2022-08-02
EP4218807A2 (en) 2023-08-02
ES2941967T3 (es) 2023-05-29
EP3393510B1 (en) 2023-02-22
US11219681B2 (en) 2022-01-11
EP4393938A3 (en) 2024-08-07
EP3393510A1 (en) 2018-10-31
US10660950B2 (en) 2020-05-26
US20180369359A1 (en) 2018-12-27
MX2018007627A (es) 2019-02-14
US20200368342A1 (en) 2020-11-26
US11406700B2 (en) 2022-08-09
US20180362937A1 (en) 2018-12-20
US20180371027A1 (en) 2018-12-27
HUE061679T2 (hu) 2023-08-28
ES2973267T3 (es) 2024-06-19
WO2017109228A1 (en) 2017-06-29
US10537630B2 (en) 2020-01-21
US20230226165A1 (en) 2023-07-20
WO2017109223A1 (en) 2017-06-29
FI3393510T3 (fi) 2023-03-22
ES2950887T3 (es) 2023-10-16
EP3393508B9 (en) 2023-09-27
EP3393506B1 (en) 2024-03-13
US20250018023A1 (en) 2025-01-16
EP3393508B1 (en) 2023-06-07
SI3393510T1 (sl) 2023-04-28
EP4357355A2 (en) 2024-04-24
KR20180097558A (ko) 2018-08-31
US20230056142A1 (en) 2023-02-23
US20190008945A1 (en) 2019-01-10
EP4218807A3 (en) 2023-09-06
EP3393509C0 (en) 2024-02-28
EP3393508A1 (en) 2018-10-31
WO2017109224A1 (en) 2017-06-29
DK3393510T5 (da) 2024-09-30
US11524064B2 (en) 2022-12-13
US20240108712A1 (en) 2024-04-04
CA3009278A1 (en) 2017-06-29
LT3393510T (lt) 2023-03-27
HRP20230273T1 (hr) 2023-04-28
US12005111B2 (en) 2024-06-11
US10639365B2 (en) 2020-05-05
CN108697785A (zh) 2018-10-23
EP3393506C0 (en) 2024-03-13
EP3393507C0 (en) 2024-02-07
WO2017109229A1 (en) 2017-06-29
US20220273786A1 (en) 2022-09-01
EP3393508C0 (en) 2023-06-07

Similar Documents

Publication Publication Date Title
BR112018012873A2 (pt) vacina de vírus zika
IL270090B (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
IL255106A0 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
BR112014028476A2 (pt) fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito
EP3012322A4 (en) GENEELED STRAIN VARIANT OF PORCINE PSEUDORABIES VIRUS, VACCINE COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND USE THEREOF
MX386142B (es) COMPOSICIONES INMUNOGÉNICAS PARA EL CORONAVIRUS DEL SÍNDROME RESPIRATORIO DE ORIENTE MEDIO (MERS-CoV) Y SUS USOS.
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
MX2016017311A (es) Composiciones de portador-anticuerpo y metodos para realizarlas y utilizarlas.
BR112018008090A2 (pt) vacina de vírus do herpes simplex.
EP3344291A4 (en) VACCINE COMPOSITIONS WITH IMPROVED STABILITY AND IMMUNOGENICITY
EP2985288A4 (en) PIGS PSEUDORABIESVIRUS, VACCINE COMPOSITION, AND METHOD OF PREPARATION AND USE THEREOF
DK3244917T5 (da) Immunogene sammensætninger til anvendelse i pneumokokvacciner
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
EP3419660A4 (en) NOVEL VACCINES AGAINST ZIKA VIRUS
BR112016015422A2 (pt) formulações de vacina de frasco único
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
MX387421B (es) Producción de virus en huevos aviares.
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CL2018000609A1 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue.
MX2019005102A (es) Poxvirus quimericos sinteticos.
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
MX377258B (es) Composiciones de vectores poxvirus y su uso para inducir una respuesta inmunitaria.
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
UY36617A (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
DK3146042T3 (da) Rekombinant klassisk svinepestvirus (CSFV) med substitution i E2-proteinets TAV-epitop

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]